Ultragenyx Pharmaceutical Inc. — Balance Sheet Charts
8 snapshots of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Assets vs Liabilities
Cash Position Breakdown
Working Capital Components
Total Assets↑+1.9% +$29M
$1.53B
Current Assets↑+16.4% +$134M
$951M
Cash & Equivalents↑+142.0% +$247M
$421M
ST Investments
—
Receivables↑+29.5% +$36M
$158M
Inventory↑+15.6% +$7M
$52M
Net PPE↓-8.3% -$22M
$244M
Goodwill↑+0.0% +$0
$44M
Intangibles↓-1.1% -$2M
$176M
Total Liabilities↑+29.3% +$364M
$1.60B
Current Liabilities↑+11.6% +$40M
$384M
Account Payables↓-20.5% -$8M
$31M
Stockholders Equity↓-131.4% -$335M
$-80M
Retained Earnings↓-14.5% -$575M
$-4.53B
Operating Lease ROU Asset↓-11.5% -$3M
$23M
Operating Lease Liability↑+20.0% +$6M
$36M
Gross PP&E↑+0.5% +$2M
$380M
Accumulated Depreciation↑+21.4% +$24M
$136M
Inventory WIP↑+22.7% +$5M
$27M
Inventory Finished Goods↑+8.7% +$2M
$25M
Contract Asset
—
Contract Liability
—
Contract Liability (Current)
—